Axogen Inc (AXGN)

$35.38 +0.08 (0.23%)
Market Cap 1.63B
Revenue (ttm) 187.34M
Net Income (ttm) -9.96M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 205.94
Profit Margin -5.32%
Debt to Equity Ratio 0.40
Volume 1,671,400
Avg Vol 900,522
Day's Range N/A - N/A
Shares Out 46.12M
Stochastic %K 90%
Beta 1.00
Analysts Strong Sell
Price Target $37.60

Company Profile

Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral...

Industry: Medical Devices
Sector: Healthcare
Phone: 386 462 6800
Fax: 386 462 6801
Address:
13631 Progress Boulevard, Suite 400, Alachua, United States
LuckEtradER
LuckEtradER Feb. 23 at 10:22 PM
$AXGN 👀
0 · Reply
dustin1101
dustin1101 Feb. 20 at 6:02 PM
$AXGN Umm they're already profitable bub. Or should I say bot?
0 · Reply
dipmilo
dipmilo Feb. 20 at 4:26 PM
$AXGN Axogen develops nerve repair solutions. Growth depends on procedure volumes. Profitability remains a long-term goal.
0 · Reply
dustin1101
dustin1101 Feb. 20 at 4:23 PM
$AXGN Could be the day.. make a hell of a weekly candle.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 19 at 5:15 PM
$AXGN Current Stock Price: $35.29 Contracts to trade: $35.0 AXGN Feb 20 2026 Call Entry: $0.35 Exit: $0.55 ROI: 58% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
dustin1101
dustin1101 Feb. 19 at 3:58 PM
$AXGN Any lick of real buy volume and this breaks out. Whenever the big $ decides they are done wringing out shares at these levels…
0 · Reply
erevnon
erevnon Feb. 19 at 2:52 PM
Wells Fargo initiates coverage on Axogen $AXGN at Overweight rating and announces a price target of https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
RuleBasedReturns
RuleBasedReturns Feb. 18 at 4:23 PM
$AXGN Axogen develops nerve repair solutions with exposure to surgical procedure volumes. Growth depends on surgeon adoption and reimbursement consistency. Operating leverage improves as utilization scales.
0 · Reply
TheMarketsTheTarget
TheMarketsTheTarget Feb. 18 at 10:45 AM
$AXGN Solid tech Solid company Gap at 18.06. Watching close.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 17 at 3:43 PM
$AXGN RSI: 49.58, MACD: 0.5218 Vol: 0.99, MA20: 33.90, MA50: 32.58 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
1 · Reply
Latest News on AXGN
First Eagle Small Cap Opportunity Fund Q4 2025 Portfolio Review

Feb 19, 2026, 2:27 PM EST - 4 days ago

First Eagle Small Cap Opportunity Fund Q4 2025 Portfolio Review

BLZE FORM HL JBI KALU MTA OUT

Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences

Feb 17, 2026, 7:00 AM EST - 6 days ago

Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences

Axogen, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

Feb 10, 2026, 7:00 AM EST - 13 days ago

Axogen, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

Wasatch Micro Cap Fund Q4 2025 Performance Review

Feb 4, 2026, 8:35 AM EST - 19 days ago

Wasatch Micro Cap Fund Q4 2025 Performance Review

BLZE CLMB CSTL MAMA VITL

Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock

Jan 21, 2026, 11:18 PM EST - 4 weeks ago

Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock

Axogen Announces Proposed Public Offering of Common Stock

Jan 21, 2026, 4:09 PM EST - 4 weeks ago

Axogen Announces Proposed Public Offering of Common Stock

Axogen, Inc. (AXGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 15, 2026, 5:25 PM EST - 5 weeks ago

Axogen, Inc. (AXGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025

Jan 12, 2026, 7:00 AM EST - 6 weeks ago

Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025

Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)

Dec 3, 2025, 8:01 PM EST - 2 months ago

Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)

FDA approves Axogen's nerve repair graft

Dec 3, 2025, 6:53 PM EST - 2 months ago

FDA approves Axogen's nerve repair graft

Avance Nerve Graft FDA Verdict Approaches, Why Investors Are Watching Axogen

Dec 1, 2025, 12:33 PM EST - 3 months ago

Avance Nerve Graft FDA Verdict Approaches, Why Investors Are Watching Axogen

Wasatch Micro Cap Value Fund Q3 2025 Contributors And Detractors

Nov 5, 2025, 2:19 PM EST - 3 months ago

Wasatch Micro Cap Value Fund Q3 2025 Contributors And Detractors

BELFB LMB PMTS WLDN

Axogen, Inc. (AXGN) Q3 2025 Earnings Call Transcript

Oct 29, 2025, 2:26 PM EDT - 4 months ago

Axogen, Inc. (AXGN) Q3 2025 Earnings Call Transcript

Axogen, Inc. Reports Third Quarter 2025 Financial Results

Oct 29, 2025, 7:00 AM EDT - 4 months ago

Axogen, Inc. Reports Third Quarter 2025 Financial Results

Axogen, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – AXGN

Oct 1, 2025, 12:30 PM EDT - 5 months ago

Axogen, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – AXGN

AXGN Investors Have Opportunity to Join Axogen, Inc. Fraud Investigation with the Schall Law Firm

Oct 1, 2025, 10:50 AM EDT - 5 months ago

AXGN Investors Have Opportunity to Join Axogen, Inc. Fraud Investigation with the Schall Law Firm

Axogen Provides Update on FDA Review Timeline for Avance Nerve Graft

Aug 25, 2025, 6:40 AM EDT - 6 months ago

Axogen Provides Update on FDA Review Timeline for Avance Nerve Graft

Axogen: Broad Range Of Outcomes Still Present, Opting To Remain Sidelined

Aug 12, 2025, 5:17 AM EDT - 6 months ago

Axogen: Broad Range Of Outcomes Still Present, Opting To Remain Sidelined

Axogen, Inc. (AXGN) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 1:15 PM EDT - 7 months ago

Axogen, Inc. (AXGN) Q2 2025 Earnings Call Transcript

Axogen, Inc. to participate at the Canaccord Genuity 45th Annual Growth Conference

Jul 29, 2025, 4:10 PM EDT - 7 months ago

Axogen, Inc. to participate at the Canaccord Genuity 45th Annual Growth Conference

Axogen, Inc. to report 2025 second quarter financial results on August 5, 2025

Jul 22, 2025, 4:05 PM EDT - 7 months ago

Axogen, Inc. to report 2025 second quarter financial results on August 5, 2025

Axogen, Inc to Participate at Goldman Sachs Global Healthcare Conference

May 28, 2025, 8:00 AM EDT - 9 months ago

Axogen, Inc to Participate at Goldman Sachs Global Healthcare Conference

Axogen, Inc. (AXGN) Q1 2025 Earnings Call Transcript

May 9, 2025, 3:21 PM EDT - 10 months ago

Axogen, Inc. (AXGN) Q1 2025 Earnings Call Transcript

Axogen, Inc. Reports 2025 First Quarter Financial Results

May 8, 2025, 7:05 AM EDT - 10 months ago

Axogen, Inc. Reports 2025 First Quarter Financial Results

Axogen, Inc. to report 2025 first quarter financial results on May 8, 2025

Apr 24, 2025, 8:04 AM EDT - 10 months ago

Axogen, Inc. to report 2025 first quarter financial results on May 8, 2025

Axogen, Inc. (AXGN) Q4 2024 Earnings Call Transcript

Feb 25, 2025, 1:58 PM EST - 1 year ago

Axogen, Inc. (AXGN) Q4 2024 Earnings Call Transcript

Axogen, Inc. To Host Analyst & Investor Day on March 4th

Feb 25, 2025, 7:10 AM EST - 1 year ago

Axogen, Inc. To Host Analyst & Investor Day on March 4th

Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025

Feb 11, 2025, 4:58 PM EST - 1 year ago

Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025

Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jan 10, 2025, 5:00 PM EST - 1 year ago

Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Axogen: Well Placed To Capitalize Growth At Higher Multiples

Jan 6, 2025, 8:01 PM EST - 1 year ago

Axogen: Well Placed To Capitalize Growth At Higher Multiples

Axogen, Inc (AXGN) Q3 2024 Earnings Call Transcript

Nov 9, 2024, 9:53 AM EST - 1 year ago

Axogen, Inc (AXGN) Q3 2024 Earnings Call Transcript

Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft®

Sep 6, 2024, 7:00 AM EDT - 1 year ago

Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft®

Apple, Inc. (AXGN) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 2:10 PM EDT - 1 year ago

Apple, Inc. (AXGN) Q2 2024 Earnings Call Transcript

Axogen, Inc. Announces New Leadership Appointments

Aug 8, 2024, 7:05 AM EDT - 1 year ago

Axogen, Inc. Announces New Leadership Appointments

Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024

Jul 23, 2024, 7:00 AM EDT - 1 year ago

Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024

Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4)

Jul 1, 2024, 7:00 AM EDT - 1 year ago

Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4)

Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix™

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix™

Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia

May 28, 2024, 4:30 PM EDT - 1 year ago

Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia

AxoGen, Inc. (AXGN) Q1 2024 Earnings Call Transcript

May 5, 2024, 1:21 AM EDT - 1 year ago

AxoGen, Inc. (AXGN) Q1 2024 Earnings Call Transcript

Axogen, Inc Reports First Quarter 2024 Financial Results

May 2, 2024, 7:00 AM EDT - 1 year ago

Axogen, Inc Reports First Quarter 2024 Financial Results

Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™

Apr 29, 2024, 4:50 PM EDT - 1 year ago

Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™

Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024

Apr 16, 2024, 7:00 AM EDT - 2 years ago

Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024

AxoGen, Inc. (AXGN) Q4 2023 Earnings Call Transcript

Mar 5, 2024, 11:03 AM EST - 2 years ago

AxoGen, Inc. (AXGN) Q4 2023 Earnings Call Transcript

Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results

Mar 5, 2024, 7:00 AM EST - 2 years ago

Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results

Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024

Feb 13, 2024, 4:30 PM EST - 2 years ago

Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024

Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Feb 2, 2024, 4:15 PM EST - 2 years ago

Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap

Jan 18, 2024, 5:00 PM EST - 2 years ago

Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap

Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023

Jan 4, 2024, 4:45 PM EST - 2 years ago

Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023

LuckEtradER
LuckEtradER Feb. 23 at 10:22 PM
$AXGN 👀
0 · Reply
dustin1101
dustin1101 Feb. 20 at 6:02 PM
$AXGN Umm they're already profitable bub. Or should I say bot?
0 · Reply
dipmilo
dipmilo Feb. 20 at 4:26 PM
$AXGN Axogen develops nerve repair solutions. Growth depends on procedure volumes. Profitability remains a long-term goal.
0 · Reply
dustin1101
dustin1101 Feb. 20 at 4:23 PM
$AXGN Could be the day.. make a hell of a weekly candle.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 19 at 5:15 PM
$AXGN Current Stock Price: $35.29 Contracts to trade: $35.0 AXGN Feb 20 2026 Call Entry: $0.35 Exit: $0.55 ROI: 58% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
dustin1101
dustin1101 Feb. 19 at 3:58 PM
$AXGN Any lick of real buy volume and this breaks out. Whenever the big $ decides they are done wringing out shares at these levels…
0 · Reply
erevnon
erevnon Feb. 19 at 2:52 PM
Wells Fargo initiates coverage on Axogen $AXGN at Overweight rating and announces a price target of https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
RuleBasedReturns
RuleBasedReturns Feb. 18 at 4:23 PM
$AXGN Axogen develops nerve repair solutions with exposure to surgical procedure volumes. Growth depends on surgeon adoption and reimbursement consistency. Operating leverage improves as utilization scales.
0 · Reply
TheMarketsTheTarget
TheMarketsTheTarget Feb. 18 at 10:45 AM
$AXGN Solid tech Solid company Gap at 18.06. Watching close.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 17 at 3:43 PM
$AXGN RSI: 49.58, MACD: 0.5218 Vol: 0.99, MA20: 33.90, MA50: 32.58 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
1 · Reply
dustin1101
dustin1101 Feb. 13 at 5:07 PM
$AXGN Lots of fearful shares have found new homes this week. Will make the next move upward that much quicker..
0 · Reply
dustin1101
dustin1101 Feb. 11 at 8:20 PM
$AXGN nearly green after that nonsense. If this closes the week over $35 it’s going to make one hell of a hammer on the chart.
0 · Reply
dustin1101
dustin1101 Feb. 11 at 3:58 PM
$AXGN They flushed that stop loss handily. Wow. What an opportunity.
0 · Reply
dustin1101
dustin1101 Feb. 11 at 3:27 PM
$AXGN Adding this dip.
0 · Reply
dustin1101
dustin1101 Feb. 10 at 5:51 PM
$AXGN low vol consolidation in the lower end of the new range. ER in two weeks. Getting coiled for the next move.
0 · Reply
dustin1101
dustin1101 Feb. 9 at 4:48 PM
$AXGN Nice fakeout. Almost put an add order in but it ran away from me too fast.
0 · Reply
ortega1963
ortega1963 Feb. 9 at 10:23 AM
$AXGN I go Long over 36
0 · Reply
LuckEtradER
LuckEtradER Feb. 9 at 1:31 AM
$AXGN
0 · Reply
kiwitc2000
kiwitc2000 Feb. 6 at 7:38 PM
$AXGN Come on, pop already! Been setting up long enough. 😀
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 5 at 8:26 PM
$AXGN RSI: 63.97, MACD: 0.9510 Vol: 1.50, MA20: 33.13, MA50: 31.80 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
KalmanFilter
KalmanFilter Feb. 4 at 1:41 PM
$AXGN is a medical device company focused on nerve repair and protection; its addressable market is specialized, requiring a focused commercial strategy to drive penetration.
0 · Reply
Albino_Trader123
Albino_Trader123 Feb. 4 at 6:42 AM
$AXGN Still setting up nice.
0 · Reply